Mirxes
US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up
The investigation committee will oversee a review of 14 transactions and ‘associated subsequent events’
Singapore biotech Mirxes misses 2025 results deadline as auditors probe vendor payments
Trading in company’s shares is suspended until its results are published
A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows
Higher revenue is driven by increased contributions from its early detection and precision multi-omics segment
Singapore-headquartered Mirxes to join Alibaba, Tencent on Hang Seng Composite Index
Biotech firm will be part of Hong Kong market benchmark from Sep 8
Singapore biotech firm Mirxes launches IPO in Hong Kong to raise HK$1 billion
Shares are expected to start trading on May 23
‘A fighting chance’: Mirxes on why it chose Hong Kong over Singapore for its IPO
Chief executive Dr Zhou Lihan says Hong Kong offered a better valuation and a more savvy investor pool
Singapore biotech Mirxes files for Hong Kong IPO after raising US$50 million
CANCER diagnostics company Mirxes has applied to Hong Kong’s stock exchange for an initial public offering (IPO), potentially becoming the first company based outside of China and Hong Kong to list un...